Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,877 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Korean Real-World Data on Patients With Unresectable Stage III NSCLC Treated With Durvalumab After Chemoradiotherapy: PACIFIC-KR.
Park CK, Oh HJ, Kim YC, Kim YH, Ahn SJ, Jeong WG, Lee JY, Lee JC, Choi CM, Ji W, Song SY, Choi J, Lee SY, Kim H, Lee SY, Park J, Yoon SH, Joo JH, Oh IJ. Park CK, et al. Among authors: park j. J Thorac Oncol. 2023 Aug;18(8):1042-1054. doi: 10.1016/j.jtho.2023.04.008. Epub 2023 Apr 20. J Thorac Oncol. 2023. PMID: 37085032 Free article.
Randomized, Multicenter, Phase 3 Study of Accelerated Fraction Radiation Therapy With Concomitant Boost to the Gross Tumor Volume Compared With Conventional Fractionation in Concurrent Chemoradiation in Patients With Unresectable Stage III Non-Small Cell Lung Cancer: The Korean Radiation Oncology Group 09-03 Trial.
Kim YH, Ahn SJ, Moon SH, Kim JH, Kim YC, Oh IJ, Park CK, Jeong JU, Yoon MS, Song JY, Suh CO, Cho KH, Park SH. Kim YH, et al. Among authors: park ck, park sh. Int J Radiat Oncol Biol Phys. 2023 Mar 15;115(4):873-885. doi: 10.1016/j.ijrobp.2022.10.014. Epub 2022 Oct 21. Int J Radiat Oncol Biol Phys. 2023. PMID: 36280151 Clinical Trial.
Real-world analysis of first-line afatinib in patients with EGFR-mutant non-small cell lung cancer and brain metastasis: survival and prognostic factors.
Kim J, Jang TW, Choi CM, Kim MH, Lee SY, Park CK, Chang YS, Lee KY, Kim SJ, Yang SH, Ryu JS, Lee JE, Lee SY, Park CK, Lee SH, Jang SH, Yoon SH. Kim J, et al. Among authors: park ck. Transl Lung Cancer Res. 2023 Jun 30;12(6):1197-1209. doi: 10.21037/tlcr-22-832. Epub 2023 Jun 12. Transl Lung Cancer Res. 2023. PMID: 37425421 Free PMC article.
Real-world outcome of crizotinib for anaplastic lymphoma kinase-positive lung cancer: Multicenter retrospective analysis in South Korea.
Jeon DS, Park CK, Kim SJ, Park CK, Chang YS, Jung CY, Lee SY, Lee SY, Ryu JS, Lee JE, Lee KY, Jang TW, Jang SH, Yoon SH, Lee SH, Choi CM, Kim HR, Kim YJ. Jeon DS, et al. Among authors: park ck. Thorac Cancer. 2024 Feb;15(6):448-457. doi: 10.1111/1759-7714.15213. Epub 2024 Jan 3. Thorac Cancer. 2024. PMID: 38171544 Free PMC article.
Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer.
Wu YL, Dziadziuszko R, Ahn JS, Barlesi F, Nishio M, Lee DH, Lee JS, Zhong W, Horinouchi H, Mao W, Hochmair M, de Marinis F, Migliorino MR, Bondarenko I, Lu S, Wang Q, Ochi Lohmann T, Xu T, Cardona A, Ruf T, Noe J, Solomon BJ; ALINA Investigators. Wu YL, et al. N Engl J Med. 2024 Apr 11;390(14):1265-1276. doi: 10.1056/NEJMoa2310532. N Engl J Med. 2024. PMID: 38598794 Clinical Trial.
1,877 results